Cardioimmunology of Myocarditis: Targeting the IL-1 Pathway

Curr Cardiol Rep. 2026 Jul 3;28(1):64. doi: 10.1007/s11886-026-02390-4.ABSTRACTPURPOSE OF REVIEW: Myocarditis is a heterogeneous inflammatory syndrome with aetiologies ranging from viral infection and drug hypersensitivity to systemic autoimmune/autoinflammatory disease and immune checkpoint inhibit

E Emanuele Chiara

Progression inhibition in chronic kidney disease

Inn Med (Heidelb). 2026 Jul 3. doi: 10.1007/s00108-026-02145-x. Online ahead of print.ABSTRACTThe KDIGO guidelines 2024 on evaluation and treatment of chronic kidney disease (CKD) represent a comprehensive update of the 2012 guidelines, incorporating evidence from over 937 references across 197 page

J Julia Weinmann-Menke

New Drugs on the Horizon for Hypertension

Adv Kidney Dis Health. 2026 Mar 23:S2949-8139(26)00029-7. doi: 10.1053/j.akdh.2026.02.005. Online ahead of print.ABSTRACTDespite the current therapeutic options including lifestyle modifications and pharmacotherapy, blood pressure remains inadequately controlled in the majority of hypertensive indiv

G Geonte G Jackson

Primary Aldosteronism and the Kidneys

Adv Kidney Dis Health. 2026 May 8:S2949-8139(26)00065-0. doi: 10.1053/j.akdh.2026.04.001. Online ahead of print.ABSTRACTPrimary aldosteronism (PA) is the most common and modifiable form of secondary hypertension, being responsible for 5-10% of all cases of hypertension and over 20% of cases of resis

E Emily L Simms